On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. The recommended commercial dosage of Unloxcyt is 1,200 mg adm…

Benzinga

New York

United States

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Checkpoint Therapeutics (NASDAQ:CKPT)

Ad Fontes Media

Media Bias/Fact Check

The PD-L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.

Medscape

FDA Approves Cosibelimab for Cutaneous SCC

(MedPage Today) -- The FDA approved cosibelimab (Unloxcyt) for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults who are not candidates for curative surgery or radiation.
Approval of the new PD-L1 blocking...

MedPage Today

Cosibelimab OK'd for Cutaneous Squamous Cell Carcinoma

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Fortress Biotech’s 8K filing here. About Fortress Biotech (Get Free Report) Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, […]

reporter.am

Fortress Biotech (NASDAQ:FBIO) Receives FDA Approval for UNLOXCYT™ for Treatment of cSCCOn December 13, 2024, Fortress Biotech, Inc. released an 8-K filing announcing a significant development for its majority-controlled subsidiary, Checkpoint Therap

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 6,570,000 shares, an increase of 9.0% from the November 15th total of 6,030,000 shares. Based on an average daily volume of 807,000 shares, […]

wkrb13.com

Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Grows By 9.0%

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) had its price target raised by Lake Street Capital from $4.00 to $7.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital’s target price indicates a potential upside of 102.90% from the company’s previous close. […]

com-unik.info

Lake Street Capital Forecasts Strong Price Appreciation for Checkpoint Therapeutics (NASDAQ:CKPT) Stock

HC Wainwright restated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report)  in a report released on Monday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. Checkpoint Therapeutics Price Performance Shares of NASDAQ CKPT opened at $3.39 on Monday. Checkpoint Therapeutics has a 1-year low of $1.36 and a 1-year high of $4.50. The firm has a market capitalization of $165.53 million, a PE…

defenseworld.net

Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright

The FDA approved Checkpoint Therapeutics’ anti-PD-L1 antibody cosibelimab in a form of advanced skin cancer, the company announced Friday. The immune checkpoint drug will be marketed as Unloxcyt and will be administered as an IV infusion.

Endpoints News

Checkpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer, seeks partner for launch

WALTHAM, Mass., Dec.  13, 2024  (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death li…

ADKhabar

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(cosibelimab-ipdl)

The indication is for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection - Checkpoint Therapeutics (NASDAQ:CKPT)

Coverage Details

Give the gift of Perspective

Bias Distribution

Ownership

Similar News Topics

Similar News Topics